Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma

Completed · Phase 2

Conditions studied: Biliary Cancer, Cholangiocarcinoma

In brief

This study evaluates the combination chemotherapy with gemcitabine, irinotecan and panitumumab in patients with advanced biliary cancer.

Key facts

Study ID

NCT00948935

Run by

Abramson Cancer Center at Penn Medicine

People needed

35

Starts

2009-04-01

Expected to finish

2014-09-26

Last updated by the study team

2020-03-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• histologically or cytologically confirmed local advanced unresectable/metastatic adenocarcinoma of biliary tract
• measurable disease
• available tumor tissue for investigational immunohistochemical evaluations
• ECOG PS 0-2
• No prior chemotherapy, biologic therapy or radiation therapy
• Age Eighteen and older
• Lab values per protocol

You may not qualify if…

• Life expectancy less than three months
• Concurrent use of chemotherapy not indicated in the study protocol or any other investigational agents and patients who have received investigational drugs less than four weeks prior to enrollment
• Prior therapy, which affects or targets the EGF pathway
• Treatment for other carcinomas within the last five years, except cured non-melanoma skin and treated in-situ cervical cancer
• Recovery from major surgery within three weeks of the start of study treatment

Where it is running

• Abramson Cancer Center at University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.